Trails Edge Capital Partners LP Purchases New Holdings in Nurix Therapeutics, Inc. $NRIX

Posted by Brenda Bartman on Aug 26th, 2026

Trails Edge Capital Partners LP purchased a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,573,220 shares of the company’s stock, valued at approximately $38,166,318. Nurix Therapeutics accounts for 0.0% of Trails Edge Capital Partners LP’s holdings, making the stock its 2nd largest position. Trails Edge Capital Partners LP owned approximately 1.52% of Nurix Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of NRIX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Nurix Therapeutics by 11.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company’s stock valued at $593,000 after buying an additional 5,286 shares in the last quarter. Millennium Management LLC grew its holdings in Nurix Therapeutics by 106.2% during the first quarter. Millennium Management LLC now owns 874,399 shares of the company’s stock valued at $10,388,000 after purchasing an additional 450,262 shares during the period. Goldman Sachs Group Inc. lifted its stake in Nurix Therapeutics by 9.5% in the first quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company’s stock worth $6,029,000 after purchasing an additional 44,002 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Nurix Therapeutics by 8.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company’s stock valued at $1,895,000 after buying an additional 12,817 shares during the last quarter. Finally, Creative Planning purchased a new position in shares of Nurix Therapeutics during the 2nd quarter valued at approximately $187,000.

Insider Activity at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 4,761 shares of the firm’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the completion of the transaction, the chief financial officer directly owned 40,166 shares in the company, valued at $978,443.76. This trade represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 4,356 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $25.00, for a total transaction of $108,900.00. Following the sale, the insider directly owned 117,227 shares of the company’s stock, valued at $2,930,675. This represents a 3.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,314 shares of company stock valued at $589,361 over the last quarter. 6.70% of the stock is owned by company insiders.

Nurix Therapeutics Stock Performance

Shares of NRIX traded down $0.67 during trading hours on Friday, reaching $26.21. 908,256 shares of the company traded hands, compared to its average volume of 1,456,283. The stock has a market cap of $2.72 billion, a P/E ratio of -7.60 and a beta of 1.79. Nurix Therapeutics, Inc. has a 1-year low of $8.19 and a 1-year high of $28.23. The stock’s fifty day moving average is $24.20 and its 200 day moving average is $18.94.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last issued its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. The firm had revenue of $9.04 million during the quarter, compared to analyst estimates of $15.29 million. On average, equities research analysts predict that Nurix Therapeutics, Inc. will post -2.73 EPS for the current year.

Analyst Ratings Changes

NRIX has been the subject of a number of research analyst reports. Mizuho upped their target price on Nurix Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. UBS Group lifted their price target on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Needham & Company LLC reissued a “buy” rating and issued a $34.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, August 4th. Robert W. Baird boosted their price target on shares of Nurix Therapeutics from $26.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Finally, Morgan Stanley lifted their price objective on Nurix Therapeutics from $36.00 to $38.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 28th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.21.

Get Our Latest Analysis on NRIX

Nurix Therapeutics Profile

(Free Report)

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.